Remibrutinib Evaluated in Phase 3 Multiple Sclerosis Trials
The study compares the efficacy of remibrutinib against teriflunomide for adults managing relapsing multiple sclerosis.
Updated on Oct. 23, 2026 in Stroke
Researchers have completed two Phase 3 clinical trials, REMODEL-1 and REMODEL-2, evaluating the efficacy of remibrutinib for patients with relapsing multiple sclerosis. The studies directly compared the performance of remibrutinib against teriflunomide.
Why it matters
For patients managing relapsing multiple sclerosis, these trials provide new comparative data on treatment options. These findings represent a significant evaluation of potential therapies within the current landscape of chronic neurological disease management.
The REMODEL-1 and REMODEL-2 trials were conducted as Phase 3 randomized clinical trials across multiple global institutions. Researchers evaluated the efficacy of remibrutinib against teriflunomide in a population of patients diagnosed with relapsing multiple sclerosis.
The players
REMODEL-1
A Phase 3 randomized clinical trial investigating the efficacy of remibrutinib in patients with relapsing multiple sclerosis.
REMODEL-2
A secondary Phase 3 randomized clinical trial comparing remibrutinib to teriflunomide in a relapsing multiple sclerosis population.
The details
The REMODEL trials investigate remibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor designed to target specific immune cells involved in the inflammatory processes of multiple sclerosis. By modulating these pathways, the drug aims to reduce disease activity compared to existing standard-of-care treatments like teriflunomide. These comparative studies seek to clarify how this specific mechanism of action holds up against established therapies in controlling relapsing symptoms.
Timeline
The clinical trial findings were reported on October 23, 2026.
Health Landscape
This research follows the established pattern of high-stakes comparative studies published in The Lancet to update the standard of care for chronic conditions. It contributes to the evolving pipeline of targeted therapies moving beyond traditional immunomodulatory treatments for multiple sclerosis.
These findings are relevant to adults currently navigating treatment decisions for relapsing multiple sclerosis. It is worth discussing with your doctor how emerging therapies like remibrutinib compare to your current regimen and if they may be appropriate for your specific case.
The takeaway
Comparative trials like REMODEL-1 and REMODEL-2 are essential for refining how we treat relapsing multiple sclerosis. Patients should keep a record of symptom changes and discuss new clinical developments with their neurologist during regular checkups.
Further reading
Learn more about the latest research and management strategies for complex neurological conditions in our Stroke section.
More information
View the full report in The Lancet clinical trial abstract02058-1/abstract).
